NeuroSearch A/S - Share purchase programme - Status update

In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a
share purchase programme under which the company will buy own shares for an
amount of up to DKK 50 million during 2009. 

The programme is structured according to European Commission Regulation No
2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules,
for the purchase of own shares. 

In the past week, since the issue of status announcement no. 35-09 of 17 August
2009, the following transactions have been made under NeuroSearch's share
purchase programme: 

Accumulated share purchase	Number of  shares	Average price (DKK)	Transaction
value (DKK) 
17 August 2009	2,000	125.75	251,500
18 August 2009	2,500	125.40	313,500
19 August 2009	1,500	124,50	186.750
20 August 2009	2,000	125.88	251.750
21 August 2009	2,085	124.64	259.874
Total 	        10,085	125.27	1,263,374


With the purchased amount of shares as stated above, NeuroSearch now holds a
total of 214,208 treasury shares of DKK 20 nominal value each, corresponding to
1.29% of the total number of 16,619,268 issued shares in NeuroSearch A/S. 

An amount of DKK 26,740,426 remains to be used under the share purchase
programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX
Copenhagen on Friday 21 August 2009, this corresponds to a maximum of 213,923
additional NeuroSearch shares to be bought under the programme. 


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4460 8212 or +45 4017 5103 



About NeuroSearch  
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company, Janssen Pharmaceutica and
GlaxoSmithKline (GSK), and a license collaboration with Abbott. NeuroSearch's
pipeline of drug candidates comprises seven clinical (Phase I-III) development
programmes: Pridopidine (ACR16) for Huntington's disease (Phase III),
tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in
partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease
(Phase Ib), ACR343 for schizophrenia (Phase II ready), ABT-560 for the
treatment of various CNS disorders (Phase I) in collaboration with Abbott, and
NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.